Free Research Report on Opko Health, Inc., ACADIA Pharmaceuticals, Inc., Simcere Pharmaceutical Group, SciClone Pharmaceuticals, Inc. and Sequenom, Inc.

News provided by

Jan 30, 2013, 08:00 ET

NEW YORK, January 30, 2013 /PRNewswire/ --

Today, Traders Insight announced new research reports highlighting Opko Health, Inc. (NYSE MKT: OPK), ACADIA Pharmaceuticals, Inc. (Nasdaq: ACAD), Simcere Pharmaceutical Group (NYSE: SCR), SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) and Sequenom, Inc. (Nasdaq: SQNM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Opko Health, Inc. Research Report
OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company that develops solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions. The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/9b21_OPK]

ACADIA Pharmaceuticals, Inc. Research Report
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/7464_ACAD]

Simcere Pharmaceutical Group Research Report
Simcere Pharmaceutical Group is a holding company. The Company principally engaged in the research, development, manufacture and distribution of pharmaceutical and vaccine products in the People's Republic of China. As of December 31, 2011, it manufactured and sold 47 pharmaceutical products and is the distributor of two additional pharmaceutical products that are marketed under its brand names. The Full Research Report on Simcere Pharmaceutical Group - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/9d9c_SCR]

SciClone Pharmaceuticals, Inc. Research Report
SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company's main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. The Full Research Report on SciClone Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/92e8_SCLN]

Sequenom, Inc. Research Report
Manufactures DNA detection and sequencing equipment. The Company's two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository. Sequenom provides genetic analysis products that translate genomic science into solutions for biomedical research, molecular medicine and agricultural applications. More from Reuters Â» The Full Research Report on Sequenom, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-29/2401_SQNM]

About Traders Insight
Our model of enabling open collaboration between members is breaking new ground into the investment community. By tapping into the resources of the community, we are crowd-sourcing our reach. As a result -- we have been able to identify some of the greatest moving companies on the market today. The evidence is in the results, join today and experience what you've been missing.